Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
I 期主动免疫疗法，将两种嵌合的人表皮生长因子受体 2 B 细胞表位与一种广谱 T 细胞表位融合，用于治疗转移性和/或复发性实体瘤患者
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2009.22.3883
Kaumaya Pravin T P, Foy Kevin Chu, Garrett Joan, Rawale Sharad V, Vicari Daniele, Thurmond Jennifer M, Lamb Tammy, Mani Aruna, Kane Yahaira, Balint Catherine R, Chalupa Donald, Otterson Gregory A, Shapiro Charles L, Fowler Jeffrey M, Grever Michael R, Bekaii-Saab Tanios S, Carson William E 3rd
